[
  {
    "ts": null,
    "headline": "Oxford Launches Regional Partnership to Drive Equitable, Innovation-Led Growth",
    "summary": "OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.",
    "url": "https://finnhub.io/api/news?id=3081391cc2eadd0c18e089b519fa5c272b153d72f3b76b24061caac4575bc0e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762798980,
      "headline": "Oxford Launches Regional Partnership to Drive Equitable, Innovation-Led Growth",
      "id": 137396949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.",
      "url": "https://finnhub.io/api/news?id=3081391cc2eadd0c18e089b519fa5c272b153d72f3b76b24061caac4575bc0e9"
    }
  },
  {
    "ts": null,
    "headline": "What Are Wall Street Analysts’ Target Price for Moderna Stock?",
    "summary": "Are Wall Street analysts favoring Moderna’s stock?",
    "url": "https://finnhub.io/api/news?id=908d138a2c17cf66f66235143e55367d853e5915e82297b0be53e1386fc20def",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762784740,
      "headline": "What Are Wall Street Analysts’ Target Price for Moderna Stock?",
      "id": 137396950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Are Wall Street analysts favoring Moderna’s stock?",
      "url": "https://finnhub.io/api/news?id=908d138a2c17cf66f66235143e55367d853e5915e82297b0be53e1386fc20def"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?",
    "summary": "In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...",
    "url": "https://finnhub.io/api/news?id=c98219ce3dc5f42ef9621fe51bd2ac982caa6ed62d6e1c6f985188365b23fdcc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762744654,
      "headline": "Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?",
      "id": 137392772,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...",
      "url": "https://finnhub.io/api/news?id=c98219ce3dc5f42ef9621fe51bd2ac982caa6ed62d6e1c6f985188365b23fdcc"
    }
  }
]